Sulfasalazine
Azulfidine, Azulfidine EN-tabs
Indications for Sulfasalazine
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Rheumatoid arthritis — inadequate response to NSAIDs | Adults | Monotherapy or combination DMARD | FDA Approved |
| Polyarticular-course juvenile idiopathic arthritis | Children ≥6 years | Second-line after NSAID failure | FDA Approved |
| Ulcerative colitis — induction and maintenance | Adults & pediatric ≥2 years | Monotherapy | FDA Approved |
Sulfasalazine is one of the oldest and most affordable conventional synthetic DMARDs. In the ACR 2021 RA guidelines, it is conditionally recommended as monotherapy for DMARD-naive patients with low disease activity and as part of triple DMARD therapy (with methotrexate and hydroxychloroquine) for moderate-to-high disease activity. Its favourable pregnancy safety profile makes it a particularly valuable option for women planning conception. For RA, only the enteric-coated delayed-release formulation (Azulfidine EN-tabs) carries the FDA-approved indication.
Ankylosing spondylitis — limited peripheral joint benefit; TNF inhibitors preferred for axial disease (evidence quality: Moderate).
Psoriatic arthritis — peripheral arthritis; endorsed by GRAPPA guidelines (evidence quality: Moderate).
Reactive arthritis — chronic or recurrent forms (evidence quality: Low).
Crohn disease — mild-to-moderate colonic disease; not FDA-approved for this indication (evidence quality: Moderate).
Dosing for Sulfasalazine
Adult — Rheumatoid Arthritis (EN-tabs only)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| RA — standard initiation | 500 mg daily or 1 g/day in 2 divided doses | 1 g BID (2 g/day) | 3 g/day | Increase weekly by 500 mg to reach maintenance Full benefit at 2–3 months; increase to 3 g/day only if inadequate response after 12 weeks |
| RA — triple DMARD therapy (with MTX + HCQ) | 500 mg daily, titrate to 1 g BID | 1 g BID (2 g/day) | 3 g/day | ACR 2021 conditionally recommends over MTX monotherapy for moderate-high activity All three drugs titrated independently based on tolerability |
| RA — GI-intolerant patients (slow escalation) | 500 mg daily | 500 mg–1 g BID | 2 g/day | Increase by 500 mg weekly; use EN-tabs (enteric-coated) formulation If intolerance persists, stop for 5–7 days then restart at lower dose |
Pediatric — JIA (≥6 years)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Polyarticular JIA | ¼ to ⅓ of planned maintenance dose | 30–50 mg/kg/day in 2 divided doses | 2 g/day | Increase weekly to reach maintenance at 1 month Avoid in systemic-course JIA — high rate of serum sickness-like reaction |
GI intolerance is the most common reason patients stop sulfasalazine within the first month. Starting at the full maintenance dose causes unnecessary nausea and dyspepsia. Instead, begin with 500 mg daily and increase by 500 mg each week until the target dose is reached. The enteric-coated EN-tabs formulation further reduces gastric irritation. Always take with food and a full glass of water. This gradual approach substantially improves adherence and is endorsed by the FDA label.
Pharmacology of Sulfasalazine
Mechanism of Action
Sulfasalazine is a prodrug consisting of sulfapyridine linked to 5-aminosalicylic acid (5-ASA) via an azo bond. After oral administration, approximately 15% of intact sulfasalazine is absorbed in the small intestine, while the majority reaches the colon where bacterial azoreductases cleave it into its two active moieties. In inflammatory bowel disease, the local anti-inflammatory effects of 5-ASA in the colonic mucosa are considered the primary therapeutic component. In rheumatoid arthritis, the mechanism is less clear but appears to involve sulfapyridine-mediated immunosuppressive effects. Proposed mechanisms include inhibition of B-cell immunoglobulin production, suppression of T-cell proliferation, inhibition of NF-kB activation, reduction in pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha), interference with folate-dependent pathways, and inhibition of neutrophil chemotaxis. Sulfasalazine also inhibits the cystine-glutamate antiporter (system xc-), which may contribute to its immunomodulatory properties.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ~15% of intact SSZ absorbed in small intestine; remainder reaches colon for bacterial cleavage; sulfapyridine well absorbed after release; Tmax 3–12 h (sulfapyridine) | EN-tabs bypass gastric dissolution to reduce upper GI side effects; food does not significantly affect overall absorption |
| Distribution | SSZ: >99% protein-bound; sulfapyridine: ~70% protein-bound; SSZ and metabolites cross placenta and enter breast milk (sulfapyridine in milk: 30–60% of maternal serum) | Very high SSZ protein binding rarely clinically relevant; sulfapyridine levels in breast milk are low; poor bilirubin-displacing capacity of sulfapyridine makes it relatively safe in neonates |
| Metabolism | Colonic bacterial azoreductases cleave SSZ to sulfapyridine + 5-ASA; sulfapyridine undergoes hepatic N4-acetylation (acetylator phenotype-dependent) and hydroxylation; 5-ASA undergoes N-acetylation in liver and intestine | Slow acetylators have higher sulfapyridine levels and greater incidence of adverse effects; serum sulfapyridine >50 mcg/mL associated with increased toxicity |
| Elimination | Sulfapyridine t½: 10.4 h (fast) / 14.8 h (slow acetylators); parent SSZ t½: ~6 h; renal excretion of sulfapyridine metabolites; 5-ASA mostly excreted in faeces | Adequate hydration required to prevent crystalluria and kidney stones; shorter half-life compared to other DMARDs means effects resolve within days of stopping |
Side Effects of Sulfasalazine
The following RA-specific incidence data are from clinical trials of sulfasalazine in rheumatoid arthritis as reported in the FDA-approved prescribing information. Approximately 25% of patients experience significant side effects overall, and 20–30% discontinue treatment due to adverse reactions, most within the first 3 months.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 19% | Most common early side effect; improves with slow titration, EN-tabs, and food; may respond to temporary dose reduction |
| Dyspepsia | 13% | Enteric-coated formulation substantially reduces gastric irritation |
| Rash | 13% | Usually maculopapular and pruritic; typically early in therapy; discontinue if severe; distinguish from DRESS |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | 9% | Usually self-limiting; may be dose-related |
| Abdominal pain | 8% | Take with food; gradual titration helps |
| Vomiting | 8% | If persistent, stop for 5–7 days and restart at lower dose |
| Anorexia / loss of appetite | ~8% | Usually improves with continued therapy |
| Fever | 5% | May indicate hypersensitivity reaction — evaluate promptly |
| Dizziness | 4% | Self-limiting |
| Stomatitis | 4% | Related to folate antagonism; folic acid supplementation may help |
| Pruritus | 4% | May be independent of rash; monitor for evolving skin reaction |
| Abnormal liver function tests | 4% | Usually transient; monitor per FDA schedule; hepatotoxicity rare but serious |
| Reversible oligospermia | Common in males | Reduced sperm count and motility; reversible within 2–3 months of discontinuation; counsel male patients planning conception |
| Orange discolouration of urine, tears, skin | Common | Harmless; warn patients to prevent alarm; may stain contact lenses and clothing |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Agranulocytosis / aplastic anaemia / leukopenia | Rare (~1 in 30 or less for Heinz body/hemolytic anaemia; agranulocytosis very rare) | Usually within first 3 months | Immediate discontinuation; CBC monitoring; supportive care; sore throat, pallor, or purpura are warning signs |
| DRESS (drug reaction with eosinophilia and systemic symptoms) | Rare | Usually first month; may present with fever and lymphadenopathy without rash | Immediate discontinuation; hospitalisation may be needed; systemic corticosteroids |
| Stevens-Johnson syndrome / TEN / AGEP | Very rare | First month of therapy (highest risk) | Immediate discontinuation; emergency dermatologic care; potentially fatal |
| Hepatotoxicity (hepatitis, liver failure) | Rare | Variable; may present with jaundice, abnormal LFTs | Discontinue immediately; monitor LFTs; deaths have been reported from hepatic damage |
| Renal toxicity (crystalluria, nephrolithiasis, nephritis) | Rare | Any time; risk increases with dehydration | Maintain adequate hydration; monitor urinalysis and renal function; discontinue if nephritis develops |
| Pulmonary toxicity (fibrosing alveolitis, eosinophilic pneumonia) | Very rare | Variable | Discontinue; chest imaging; respiratory support; deaths have been reported |
| Myocarditis | Very rare | Variable | Discontinue; cardiology assessment; echocardiography |
Nausea, dyspepsia, and vomiting affect up to one-third of patients and are the primary reason for early discontinuation. Three practical strategies significantly improve tolerability: (1) slow dose escalation starting at 500 mg/day, (2) using the enteric-coated EN-tabs formulation, and (3) always taking with food and a full glass of water. If symptoms persist despite these measures, stop sulfasalazine for 5–7 days, then restart at a lower dose with slower titration. Desensitisation protocols (starting at 50–250 mg daily and doubling every 4–7 days) have been reported effective in 60–95% of sensitive patients.
Drug Interactions with Sulfasalazine
Sulfasalazine’s interaction profile is driven primarily by its sulfapyridine component (folate antagonism, protein-binding displacement) and its effects on drug absorption. It is a substrate and inhibitor of BCRP (breast cancer resistance protein) and OATP1B1/B3 transporters.
Monitoring for Sulfasalazine
- CBC with differentialBaseline, then q2w × 3 months, monthly × 3 months, then q3 months
RoutineMost critical monitoring parameter; agranulocytosis and aplastic anaemia are rare but potentially fatal. Sore throat, fever, pallor, or purpura warrant immediate CBC. Discontinue while awaiting results if blood dyscrasia is suspected - LFTsBaseline, then q2w × 3 months, monthly × 3 months, then q3 months
RoutineFollow same schedule as CBC; hepatotoxicity is rare but can be fatal; jaundice is a warning sign - Urinalysis & renal functionBaseline, then periodically
RoutineScreen for crystalluria, proteinuria, and renal impairment; maintain adequate hydration throughout therapy - Serum sulfapyridine levelIf toxicity suspected
Trigger-basedLevels >50 mcg/mL associated with increased adverse effects; particularly useful in slow acetylators or patients on high doses - G6PD statusBaseline (consider in at-risk populations)
Trigger-basedSulfasalazine can cause haemolytic anaemia in G6PD-deficient patients; consider screening in populations with higher prevalence
Contraindications & Cautions for Sulfasalazine
Absolute Contraindications
- Hypersensitivity to sulfasalazine, sulfonamides, or salicylates
- Intestinal obstruction or urinary obstruction
- Porphyria
Relative Contraindications (Specialist Input Recommended)
- Hepatic impairment — increased risk of hepatotoxicity
- Renal impairment — risk of crystalluria and reduced drug clearance
- Blood dyscrasias — pre-existing bone marrow suppression
- G6PD deficiency — risk of haemolytic anaemia
- Systemic-course JIA — high rate of serum sickness-like reaction; avoid in this subtype
Use with Caution
- Asthma — salicylate sensitivity may trigger bronchospasm
- Slow acetylators — higher sulfapyridine levels and more adverse effects
- Males planning conception — reversible oligospermia; discuss alternatives or timing
- Pregnancy — considered safe (Category B) but supplement folic acid due to anti-folate effects; neural tube defects reported rarely
Deaths have been reported from hypersensitivity reactions, agranulocytosis, aplastic anaemia, other blood dyscrasias, renal and liver damage, irreversible neuromuscular and CNS changes, and fibrosing alveolitis. The occurrence of sore throat, fever, pallor, purpura, or jaundice may indicate serious blood disorders or hepatotoxicity — discontinue treatment while awaiting test results. DRESS, SJS, and TEN can be fatal; highest risk in the first month of treatment.
Patient Counselling for Sulfasalazine
Purpose of Therapy
Explain that sulfasalazine works slowly to calm the immune system and reduce joint damage in rheumatoid arthritis. It is not a painkiller — its purpose is to modify the disease itself. Improvement is typically noticed after 2–3 months of consistent use. It is important to continue taking it even when feeling well, as stopping may allow the disease to flare.
How to Take
Take sulfasalazine with food and a full glass of water. Swallow enteric-coated tablets whole — do not crush or chew. Drink plenty of fluids throughout the day to protect the kidneys. Take doses evenly spaced through the day (typically twice daily for RA).
Sources
- Azulfidine EN-tabs (sulfasalazine delayed-release tablets) — Full Prescribing Information. Pfizer. DailyMed Primary source for FDA-approved RA indication, dosing schedule, adverse reaction rates, monitoring requirements, and drug interactions.
- Azulfidine (sulfasalazine tablets) — Full Prescribing Information. Pfizer. Revised 2012. FDA Label PDF Additional prescribing information for the immediate-release formulation with adverse event data applicable to UC and RA.
- Weinblatt ME, Reda D, Henderson W, et al. Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. J Rheumatol. 1999;26(10):2123-2130. PubMed Meta-analysis of 15 RCTs establishing sulfasalazine efficacy for RA clinical outcomes including tender joints, ESR, and pain.
- Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Sulfasalazine for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2000;(2):CD000958. DOI Cochrane systematic review of 6 trials (n=468) confirming statistically significant benefit over placebo; withdrawal OR 3.0 for adverse events.
- O’Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996;334(20):1287-1291. DOI Landmark trial establishing superiority of triple DMARD therapy (MTX + SSZ + HCQ) over either component alone in RA.
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924-939. DOI Current ACR guideline conditionally recommending sulfasalazine as monotherapy or in triple DMARD combination for RA.
- Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. DOI EULAR RA management recommendations including sulfasalazine as a csDMARD option.
- Smedegard G, Bjork J. Sulphasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol. 1995;34(Suppl 2):7-15. DOI Review of proposed mechanisms of sulfasalazine in RA including NF-kB inhibition, cytokine suppression, and effects on neutrophil chemotaxis.
- Padda IS, Goyal A. Sulfasalazine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. StatPearls Comprehensive review of sulfasalazine pharmacology, pharmacokinetics, dosing, adverse effects, and monitoring requirements.
- Pullar T, Hunter JA, Capell HA. Which component of sulphasalazine is active in rheumatoid arthritis? BMJ. 1985;290(6481):1535-1538. DOI Classic study demonstrating that sulfapyridine, not 5-ASA, is the active component of sulfasalazine in RA.
- Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. BMJ. 1986;293(6544):420-423. DOI Large UK cohort study documenting long-term adverse reaction profile; most reactions within 3 months; 20-30% discontinuation rate.